INDICATION

JULUCA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for ≥6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of JULUCA. JULUCA should be taken with a meal

 

ARVs=antiretrovirals.

INDICATION

JULUCA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for ≥6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of JULUCA. JULUCA should be taken with a meal

ARVs=antiretrovirals.

Discover JULUCA

100-Week Long-Term Data

Learn more about the virologic efficacy, safety, and resistance data for JULUCA

ACCESS HERE

Read more »

Risks and Side Effects

Potential risks and side effects for JULUCA

LEARN MORE

Read more »

Patient-Reported Outcomes

Explore patient-reported outcomes for JULUCA through 100 weeks

VIEW DATA

Read more »

A deeper look at JULUCA

REQUEST A ViiV REPRESENTATIVE

Have questions about JULUCA? Speak with a ViiV Representative in person

Read more »

Patient Support

Learn more about the programs available for prescribed patients

Read more »